ARMP – armata pharmaceuticals, inc. (US:AMEX)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

ARMP

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/19

07:00 am

armp

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Medium Report

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Report

3/16

01:31 pm

armp

Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]

Low Report

Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]

Report

3/12

03:41 pm

armp

Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]

Medium Report

Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]

Report

3/2

10:42 am

armp

H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]

Medium Report

H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]

Report

2/23

07:00 am

armp

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Medium Report

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Report

1/13

07:21 am

armp

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]

High Report

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus [Yahoo! Finance]

Report

1/13

07:00 am

armp

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Medium Report

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.